CoChat
Sign Up
Cited by 24Veterinary Medicine and SurgeryAdipokines, Inflammation, and Metabolic DiseasesHuman-Animal Interaction Studies

Serum adipokine concentrations in dogs with naturally occurring pituitary-dependent hyperadrenocorticism

Open access
Cho, K.-D., Paek, J., Kang, J.-H., Chang, D., Na, K.-J., Yang, M.-P.·2014·Journal of Veterinary Internal Medicine
DOI 10.1111/jvim.12270PMC PMC4857983
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: An excess of intra-abdominal fat is observed frequently in dogs with hyperadrenocorticism (HAC). Adipokine dysregulation is a possible cause of complications related to visceral obesity, but little information is available on adipokine in dogs with naturally occurring HAC. Objectives: To examine the differences in the circulating adipokines concentrations in overweight dogs with and without pituitary-dependent HAC (PDH). Animals: Thirty healthy dogs and 15 client-owned dogs with PDH. Methods: Case–controlled observational study, which enrolled 15 overweight dogs diagnosed with PDH and 30 otherwise healthy dogs of similar body condition score. Nine of 15 dogs with PDH were treated with low-dose trilostane twice daily and reassessed after treatment. Results: The serum leptin (P < .0001) and insulin (P < .0001) concentrations were significantly higher in the PDH group (leptin, 22.8 ± 8.8 [mean ± SD]; insulin, 9.1 ± 6.1) than the healthy group (leptin, 4.9 ± 3.7; insulin, 1.9 ± 0.9). However, there were no significant differences in the adiponectin, resistin, tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-10, and IL-18 levels between the 2 groups. In the PDH group, the serum cortisol concentrations had a linear association with the leptin concentrations, and there were significant decreases in the leptin (P = .0039) and insulin (P = .0039) levels after trilostane treatment. However, the leptin and insulin levels remained higher after trilostane treatment than in healthy control dogs with similar body condition score. Conclusions and Clinical Importance: Hypercortisolemia in dogs with PDH might upregulate the circulating leptin levels. However, a large population-based study will be necessary to determine whether the upregulation of leptin is involved directly with the complications caused by HAC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jvim.12270

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Obesity comorbidities include osteoarthritis and endocrine diseases such as hypothyroidism, diabetes mellitus, and hyperadrenocorticism.

    “Obesity comorbidities include osteoarthritis and endocrine diseases (e.g., hypothyroidism, diabetes mellitus, hyperadrenocorticism).37–40”

    From 2021 AAHA Nutrition and Weight Management Guidelines for Dogs and Cats (2021) · cites this paper as [40]

    The introductory passage under Conclusions and Clinical Importance (page unavailable) links visceral adiposity in dogs with diabetes mellitus and hypothyroidism, and describes visceral obesity as a sign of hyperadrenocorticism. It does not address osteoarthritis, and it presents obesity as a consequence of hyperadrenocorticism rather than establishing hyperadrenocorticism as a complication of obesity. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

  • In some cases, such as feline diabetes mellitus, preventing obesity may help reduce risk of developing the comorbidity; in others, such as hypothyroidism, the underlying condition continues to predispose to obesity unless managed.

    “In some cases (e.g., feline diabetes mellitus), preventing obesity may help reduce the risk of developing the comorbidity, whereas in others (e.g., hypothyroidism), the underlying condition will continue to predispose to obesity development unless adequately managed.”

    From 2021 AAHA Nutrition and Weight Management Guidelines for Dogs and Cats (2021) · cites this paper as [40]

    The paper’s background passage associates increased visceral adiposity with endocrine disorders including hypothyroidism, and its Discussion reports lower body weight after treatment for pituitary-dependent hyperadrenocorticism in dogs. These passages offer limited support for the idea that managing an underlying endocrine condition can affect obesity, but they do not establish that untreated hypothyroidism continues to predispose to obesity. The paper does not address whether preventing obesity reduces the risk of feline diabetes mellitus. (LLM, conf=0.78)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 45

  1. [1]Feldman EC. Distinguishing dogs with functioning adrenocortical tumors from dogs with pituitary‐dependent hyperadrenocorticism. J Am Vet Med Assoc 1983; 183: 195– 200. 6309721
  2. [2]Reusch CE, Feldman EC. Canine hyperadrenocorticism due to adrenocortical neoplasia. Pretreatment evaluation of 41 dogs. J Vet Intern Med 1991; 5: 3– 10. 1850483
  3. [3]Guptill L, Scott‐Moncrieff JC, Widmer WR. Diagnosis of canine hyperadrenocorticism. Vet Clin North Am Small Anim Pract 1997; 27: 215– 235. 9076904
  4. [4]Feldman EC, Nelson RW, Feldman MS. Use of low‐ and high‐dose dexamethasone tests for distinguishing pituitary‐dependent from adrenal tumor hyperadrenocorticism in dogs. J Am Vet Med Assoc 1996; 209: 772– 775. 8756877
  5. [5]Pan W, Kastin AJ. Adipokines and the blood brain barrier. Peptides 2007; 28: 1317– 1330. 17540480 PMC2040301
  6. [6]Radin MJ, Sharkey LC, Holycross BJ. Adipokines: A review of biological and analytical principles and an update in dogs, cats, and horses. Vet Clin Pathol 2009; 38: 136– 156. 19392760
  7. [7]O'Neill S, Drobatz K, Satyaraj E, Hess R. Evaluation of cytokines and hormones in dogs before and after treatment of diabetic ketoacidosis and in uncomplicated diabetes mellitus. Vet Immunol Immunopathol 2012; 148: 276– 283. 22840590
  8. [8]Rockall AG, Sohaib SA, Evans D, et al. Computed tomography assessment of fat distribution in male and female patients with Cushing's syndrome. Eur J Endocrinol 2003; 149: 561– 567. 14640998
  9. [9]Nishii N, Yamasaki M, Takasu M, et al. Plasma leptin concentration in dogs with diabetes mellitus. J Vet Med Sci 2010; 72: 809– 811. 20145380
  10. [10]Mazaki‐Tovi M, Feuermann Y, Segev G, et al. Increased serum leptin and insulin concentrations in canine hypothyroidism. Vet J 2010; 183: 109– 114. 18835199
  11. [11]Valassi E, Biller BM, Klibanski A, Misra M. Adipokines and cardiovascular risk in Cushing's syndrome. Neuroendocrinology 2012; 95: 187– 206. 22057123
  12. [13]Iwasaki Y, Takayasu S, Nishiyama M, et al. Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid‐activating enzyme (11beta‐hydroxysteroid dehydrogenase type 1) gene. Mol Cell Endocrinol 2008; 285: 10– 18. 18313835
  13. [14]Peterson ME, Altszuler N, Nichols CE. Decreased insulin sensitivity and glucose tolerance in spontaneous canine hyperadrenocorticism. Res Vet Sci 1984; 36: 177– 182. 6371957
  14. [15]Ortega TM, Feldman EC, Nelson RW, et al. Systemic arterial blood pressure and urine protein/creatinine ratio in dogs with hyperadrenocorticism. J Am Vet Med Assoc 1996; 209: 1724– 1729. 8921029
  15. [16]LaRue MJ, Murtaugh RJ. Pulmonary thromboembolism in dogs: 47 cases (1986–1987). J Am Vet Med Assoc 1990; 197: 1368– 1372. 2266058
  16. [17]Forrester SD, Troy GC, Dalton MN, et al. Retrospective evaluation of urinary tract infection in 42 dogs with hyperadrenocorticism or diabetes mellitus or both. J Vet Intern Med 1999; 13: 557– 560. 10587255
  17. [18]Cabrera Blatter MF, del Prado B, Miceli DD, et al. Interleukin‐6 and insulin increase and nitric oxide and adiponectin decrease in blind dogs with pituitary‐dependent hyperadrenocorticism. Res Vet Sci 2012; 93: 1195– 1202. 22381588
  18. [19]Feldman EC. Evaluation of twice‐daily lower‐dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism. J Am Vet Med Assoc 2011; 238: 1441– 1451. 21627507
  19. [20]Cho KD, Kang JH, Chang D, et al. Efficacy of low‐ and high‐dose trilostane treatment in dogs (<5 kg) with pituitary‐dependent hyperadrenocorticism. J Vet Intern Med 2013; 27: 91– 98. 23167780
  20. [21]Ishioka K, Soliman MM, Sagawa M, et al. Experimental and clinical studies on plasma leptin in obese dogs. J Vet Med Sci 2002; 64: 349– 353. 12014581
  21. [22]Schafroth U, Godang K, Ueland T, et al. Leptin levels in relation to body composition and insulin concentration in patients with endogenous Cushing's syndrome compared to controls matched for body mass index. J Endocrinol Invest 2000; 23: 349– 355. 10908161
  22. [23]Robaczyk M, Krzyzanowiska‐Swiniarska B, Andrysiak‐Mamos E, et al. Plasma leptin levels in relation to body composition and body fat distribution in patients with Cushing's syndrome. Pol Arch Med Wewn 2003; 110: 1299– 1308. 16737000
  23. [24]Masuzaki H, Ogawa Y, Hosoda K, et al. Glucocorticoid regulation of leptin synthesis and secretion in humans: Elevated plasma leptin levels in Cushing's syndrome. J Clin Endocrinol Metab 1997; 82: 2542– 2547. 9253331
  24. [25]Leal‐Cerro A, Considine RV, Peino R, et al. Serum immnoreactive‐leptin levels are increased in patients with Cushing's syndrome. Horm Metab Res 1996; 28: 711– 713. 9013748
  25. [26]Nishii N, Takasu M, Ohba Y, et al. Effects of administration of glucocorticoids and feeding status on plasma leptin concentrations in dogs. Am J Vet Res 2006; 67: 266– 270. 16454631
  26. [27]Yilmaz Z, Ilcol YO, Golcu E. Serum leptin and ghrelin levels in response to methylprednisolone injection in healthy dogs. Res Vet Sci 2007; 82: 187– 194. 17014872
  27. [28]Andrews RC, Walker BR. Glucocorticoids and insulin resistance: Old hormones, new targets. Clin Sci 1999; 96: 513– 523. 10209084
  28. [29]Ruzzin J, Wagman AS, Jensen J. Glucocorticoid‐induced insulin resistance in skeletal muscle: Defects in insulin signalling and the effects of a selective glycogen synthase kinase‐3 inhibitor. Diabetologia 2005; 48: 2119– 2130. 16078016
  29. [30]Verkest KR, Fleeman LM, Morton JM, et al. Compensation for obesity‐induced insulin resistance in dogs: Assessment of the effects of leptin, adiponectin, and glucagon‐like peptide‐1 using path analysis. Domest Anim Endocrinol 2011; 41: 24– 34. 21474268
  30. [31]Cusin I, Sainsbury A, Doyle P, et al. The ob gene and insulin. A relationship leading to clues to the understanding of obesity. Diabetes 1995; 44: 1467– 1470. 7589856
  31. [32]Laferrere B, Caixas A, Fried SK, et al. A pulse of insulin and dexamethasone stimulates serum leptin in fasting human subjects. Eur J Endocrinol 2002; 146: 839– 845. 12039705 PMC2823632
  32. [33]Katagiri H, Yamada T, Oka Y. Adiposity and cardiovascular disorder: Disturbance of the regulatory system consisting of humoral and neuronal signals. Circ Res 2007; 101: 27– 39. 17615379
  33. [34]Fischer‐Posovszky P, Wabitsch M, Hochberg Z. Endocrinology of adipose tissue – an update. Horm Metab Res 2007; 39: 314– 321. 17533572
  34. [35]Barahona MJ, Sucunza N, Resmini E, et al. Persistent body fat mass and inflammatory marker increases after long‐term cure of Cushing's syndrome. J Clin Endocrinol Metab 2009; 94: 3365– 3371. 19509101
  35. [36]Krsek M, Silha JV, Jezkova J, et al. Adipokine levels in Cushing's syndrome; Elevated resistin levels in female patients with Cushing's syndrome. Clin Endocrinol (Oxf) 2004; 60: 350– 357. 15009001
  36. [37]Brunson BL, Zhong Q, Clarke KJ, et al. Serum concentrations of adiponectin and characterization of adiponectin protein complexes in dogs. Am J Vet Res 2007; 68: 57– 62. 17199419
  37. [38]Hopkins TA, Ouchi N, Shibata R, Walsh K. Adiponectin actions in the cardiovascular system. Cardiovasc Res 2007; 74: 11– 18. 17140553 PMC1858678
  38. [39]Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose‐specific gene dysregulated in obesity. J Biol Chem 1996; 271: 10697– 10703. 8631877
  39. [40]Hotta K, Funahashi T, Bodkin NL, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001; 50: 1126– 1133. 11334417
  40. [41]Ishioka K, Omachi A, Sagawa M, et al. Canine adiponectin: cDNA structure, mRNA expression in adipose tissues and reduced plasma levels in obesity. Res Vet Sci 2006; 80: 127– 132. 16051287
  41. [42]Verkest KR, Rose FJ, Fleeman LM, et al. Adiposity and adiponectin in dogs: Investigation of causes of discrepant results between two studies. Domest Anim Endocrinol 2011; 41: 35– 41. 21645805
  42. [43]Fallo F, Scarda A, Sonino N, et al. Effect of glucocorticoids on adiponectin: A study in healthy subjects and in Cushing's syndrome. Eur J Endocrinol 2004; 150: 339– 344. 15012619
  43. [44]Libe R, Morpurgo PS, Cappiello V, et al. Ghrelin and adiponectin in patients with Cushing's disease before and after successful transsphenoidal surgery. Clin Endocrinol (Oxf) 2005; 62: 30– 36. 15638867
  44. [45]Lazar MA. Resistin‐ and obesity‐associated metabolic diseases. Horm Metab Res 2007; 39: 710– 716. 17952831
  45. [46]Schwartz DR, Lazar MA. Human resistin: Found in translation from mouse to man. Trends Endocrinol Metab 2011; 22: 259– 265. 21497511 PMC3130099

Cited by

Sorted by citations

Authors
Cho, K.-D., Paek, J., Kang, J.-H., Chang, D., Na, K.-J., & Yang, M.-P.
Affiliations
Chungbuk National University (KR)
Corresponding author
Kang, J.-H.
ORCID
Venue
Journal of Veterinary Internal Medicine
Publisher
Oxford University Press (OUP)
Published
2014-03-01
Volume
28
Issue
2
Pages
429-436
ISSN
  • 0891-6640 (ISSN-L)
  • 1939-1676
DOI
10.1111/jvim.12270
PMC
PMC4857983
OpenAlex
W1978888037
Cited by
24
References
1
Citations by year
2024: 1 · 2023: 2 · 2022: 1 · 2021: 2 · 2020: 3 · 2019: 6 · 2018: 1 · 2017: 3 · 2016: 2 · 2015: 2 · 2014: 1
FWCI
2.35
Type
journal article
Language
en
Open access
Licence
academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Locations
  • Journal of Veterinary Internal Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Research Foundation of Korea
  • Ministry of Science, ICT and Future Planning (2013R1A1A1011113)
Topics
  • Health Sciences › Veterinary › Small Animals › Veterinary Medicine and Surgery
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Human-Animal Interaction Studies
Keywords
pituitary-dependent hyperadrenocorticism, canine Cushing's disease, adipokines, leptin, insulin, hypercortisolism, trilostane, visceral obesity, adiponectin, resistin
MeSH terms
Adrenocortical Hyperfunction, Animals, Dog Diseases, Dogs, Enzyme Inhibitors, Female, Hydrocortisone, Insulin, Male, Dihydrotestosterone, Case-Control Studies, Leptin, Adipokines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review